Crinetics Pharmaceuticals, Inc. (CRNX) Operating Margin
- Operating margin · 12 months: Value -1302.52%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1302.52% | Operating income / revenue. Period ending 2026-06-30. $-549.09M ÷ $42.16M × 100 ≈ -1302.52% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -549.09M USD | Operating Income (Loss) |
| Revenue | 42.16M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 375.45M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-549.09M | $42.16M | (m) | $375.45M | (m) | -1302.52% |
| 2026-03-31 | $-545.74M | $18.07M | (m) | $355.90M | (m) | -3020.32% |
| 2025-12-31 | $-516.77M | $7.70M | (m) | $332.06M | $191.33M | -6714.77% |
| 2025-09-30 | $-477.85M | $1.53M | (m) | $313.57M | (m) | -31130.16% |
| 2025-06-30 | $-423.06M | $1.39M | (m) | $285.01M | (m) | -30392.17% |
| 2025-03-31 | $-376.73M | $760.00K | (m) | $263.06M | (m) | -49569.74% |
| 2024-12-31 | $-338.85M | $1.04M | (m) | $240.16M | (m) | -32613.47% |
| 2024-09-30 | $-306.77M | (m) | (m) | $219.17M | (m) | (m) |
| 2024-06-30 | $-277.95M | (m) | (m) | $201.10M | (m) | (m) |
| 2024-03-31 | $-248.16M | (m) | (m) | $183.40M | (m) | (m) |
| 2023-12-31 | $-222.61M | (m) | (m) | $168.53M | (m) | (m) |
| 2023-09-30 | $-207.51M | $-15.00K | (m) | $159.94M | (m) | 1383373.33% |
| 2023-06-30 | $-191.98M | $97.00K | (m) | $148.09M | (m) | -197920.62% |
| 2023-03-31 | $-182.03M | $-452.00K | (m) | $140.44M | (m) | 40272.79% |
| 2022-12-31 | $-167.88M | $0.00 | (m) | $130.22M | (m) | (m) |
| 2022-09-30 | $-151.21M | $4.03M | (m) | $117.84M | (m) | -3754.07% |
| 2022-06-30 | $-135.57M | (m) | (m) | $107.43M | (m) | (m) |
| 2022-03-31 | $-118.61M | $3.13M | (m) | $94.92M | (m) | -3788.28% |
| 2021-12-31 | $-107.70M | $0.00 | (m) | $84.25M | (m) | (m) |
| 2021-09-30 | $-98.61M | (m) | (m) | $76.48M | (m) | (m) |
| 2021-06-30 | $-89.25M | (m) | (m) | $68.60M | (m) | (m) |
| 2021-03-31 | $-80.09M | (m) | (m) | $60.72M | (m) | (m) |
| 2020-12-31 | $-74.95M | $71.00K | (m) | $57.00M | (m) | -105567.61% |
| 2020-09-30 | $-68.38M | $392.00K | (m) | $52.31M | (m) | -17442.86% |
| 2020-06-30 | $-65.15M | $897.00K | (m) | $50.44M | (m) | -7263.55% |
| 2020-03-31 | $-61.57M | $897.00K | (m) | $48.11M | (m) | -6863.99% |
| 2019-12-31 | $-53.83M | $1.19M | (m) | $41.51M | (m) | -4512.32% |
| 2019-09-30 | $-48.05M | $1.65M | (m) | $37.01M | (m) | -2906.78% |
| 2019-06-30 | $-40.89M | $1.70M | (m) | $32.08M | (m) | -2410.97% |
| 2019-03-31 | $-33.23M | $2.35M | (m) | $27.01M | (m) | -1412.15% |
| 2018-12-31 | $-28.71M | $2.43M | (m) | $24.48M | (m) | -1182.45% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $2.44M | (m) | $11.89M | (m) | (m) |
| 2017-12-31 | $-9.13M | $2.04M | (m) | $9.23M | (m) | -446.31% |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-6.04M | $589.00K | (m) | $5.10M | (m) | -1026.15% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.